Company / Current Assets
Arrowhead Pharmaceuticals Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$950.6M
FY2025
5-year range
$384.6M / $950.6M
FY2021-FY2025
Trend
+36.7%
vs FY2024
Sector context
#54 of 213
Health Care
What the data says
Arrowhead Pharmaceuticals's current assets of $951M is higher than 75% of companies in the Health Care sector (FY2025). Current Assets has increased for 8 consecutive years, from $68M in FY2017 to $951M in FY2025.
Based on SEC 10-K filings.
$951M in FY2025 with a 5-year CAGR of +24.1%. Top quartile in the Health Care sector.
Improved from $420M to $951M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +32.9%
- 5-Year CAGR
- +24.1%
- 10-Year CAGR
- -
Sector benchmark
-62.3% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's current assets has grown for 8 consecutive years.
- 5-year CAGR of +24.1%, indicating consistent growth.
- In FY2025, current assets increased 36.7% year-over-year.
- Ranks #54 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $950.6M | +36.7% |
| FY2024 | $695.5M | +65.8% |
| FY2023 | $419.5M | +3.5% |
| FY2022 | $405.3M | +5.4% |
| FY2021 | $384.6M | +19.3% |
| FY2020 | $322.4M | +21.5% |
| FY2019 | $265.2M | +236.7% |
| FY2018 | $78.8M | +16.0% |
| FY2017 | $67.9M | -25.0% |
| FY2016 | $90.5M | -12.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026